"If You Are Working On Something That You Really Care About, You Don't Have To Be Pushed. The Vision Pulls You."

– Steve Jobs

With the principle of "Unity in Diversity", Concept Medical Inc. believes in delivering the best in class medical devices with safety and care. In this booklet you will find the overview of Concept Medical Symposiums, E-Posters, Oral Presentations, Thoughtful Discussions and Audience Interaction sessions. Welcome to the World’s Biggest Academic Fiesta EURO PCR 2019.
With the rapid change in medical device industry, every now and then we experience the challenges related to the target drug delivery, bio-availability of drug and many such concerns. We at Concept Medical Inc. are always ready to see opportunity in any impossible difficulties. With our passionate, strong, focused, composed and unified aim, we are dedicated to benefit mankind in terms of medical device innovations and research. With such long years of bond with our well-wishers and opinion makers, today Concept Medical is exploring the limits of sky.

Our Approach comprises of URDDM:

- **UNDERSTANDING**
  Understand the need of innovation

- **RESEARCH**
  Research the undiscoverable

- **DEVELOPMENT**
  Developing the concept to reality

- **DELIVERING**
  Provide mankind with the best

- **MONITORING**
  Monitoring facts & figures with expertise clinical paradigm

---

"The Pessimist Sees Difficulty In Every Opportunity. The Optimist Sees Opportunity In Every Difficulty."

– Winston Churchill
21-24 May 2019
Palais des congrès de Paris,
Paris, France

BOOTH NO.
N1 & N2
Level 1
01 Symposium

Magic Touch- Sirolimus Coated Balloon
Transforming DCB Strategy: Sirolimus Coated Balloon With Nanolute Technology
Date: 21 May, 2019 | Time: 17:15 to 18:45 | Room No.: 243, Level 2.

Magic Touch PTA- Sirolimus Coated Balloon Catheter
Future And Scope Of Sirolimus Coated Balloon In Peripheral Vascular Treatment
Date: 22 May, 2019 | Time: 12:15 - 13:45 | Room No.: 253, Level 2.

Abluminus DES+
Ability To Treat Diabetic Patients: DES + DCB Strategy
Date: 23 May, 2019 | Time: 12:15 to 13:45 | Room No.: 242B, Level 2.

02 Oral Presentation session

(Dr. Sameer Dani)
Date: 23 May, 2019 | Time: 16:30 to 16:38 | Room No.: 353

03 Late Breaking Trial

Dr. Bernardo Cortese
Date: 21 May, 2019 | Time: 16:47 to 16:55 | Theatre Bordeaux, Level 3

04 E-Poster Presentation
They said put your heart into it, and we did.

#HelloFuture
TRANSFORMING DCB STRATEGY: SIROLIMUS COATED BALLOON WITH NANOLUTE TECHNOLOGY

Chairpersons:
Alexandre Abizaid, Brazil
Patrick W Serruys, Netherlands

Panellists:
Bernardo Cortese, Italy
Christoph K Naber, Germany

Key Speakers
Antonio Colombo, Aloke Finn, Azeem Latib, Bernardo Cortese, Alexandre Abizaid, Sandeep Basavarajaiah, Sameer Dani, Patrick W. Serruys.
Attend this session to:
  
  - Learn about the use of Sirolimus Coated Balloon in select indication with clinical outcomes.
  - Learn about ‘NANOLUTE’ technology applications in drug delivery and its benefits.
  - Discuss the future and scope of Sirolimus Coated Balloon in coronary interventions.

## Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:15</td>
<td>Session Objectives</td>
<td>Alexandre Abizaid</td>
</tr>
<tr>
<td>17:22</td>
<td>The MagicTouch - Sirolimus Coated Balloon: Insights from pre-clinical</td>
<td>Aloke Finn</td>
</tr>
<tr>
<td></td>
<td>evaluation</td>
<td></td>
</tr>
<tr>
<td>17:32</td>
<td>Current drug-eluting balloon indications and global data</td>
<td>Antonio Colombo</td>
</tr>
<tr>
<td>17:42</td>
<td>FDA study design and future direction</td>
<td>Azeem Latib</td>
</tr>
<tr>
<td>17:52</td>
<td>In-Stent Restenosis application: Results from NANOLUTE and EASTBOURNE</td>
<td>Bernardo Cortese</td>
</tr>
<tr>
<td></td>
<td>Trials</td>
<td></td>
</tr>
<tr>
<td>18:02</td>
<td>Case 2: First in man ISR Brazilian study, clinical and angiographic</td>
<td>Alexandre Abizaid</td>
</tr>
<tr>
<td></td>
<td>outcomes</td>
<td></td>
</tr>
<tr>
<td>18:12</td>
<td>Clinical outcomes in small vessels with MagicTouch</td>
<td>Sandeep Basavarajaiah</td>
</tr>
<tr>
<td>18:22</td>
<td>Case 3: European experience with MagicTouch in Small Vessel</td>
<td>Bernardo Cortese</td>
</tr>
<tr>
<td>18:32</td>
<td>Case 1: Bifurcation with side branch</td>
<td>Sameer Dani</td>
</tr>
<tr>
<td>18:42</td>
<td>Session evaluation and key learnings</td>
<td>Patrick W. Serruys</td>
</tr>
</tbody>
</table>
Going the extra mile; to ensure your smile.

#HelloFuture
FUTURE AND SCOPE OF SIROLIMUS COATED BALLOON IN PERIPHERAL VASCULAR TREATMENT

Chairpersons:
Antonio Colombo, Italy
Narendra Khanna, India

Panellists:
Dinesh Shah, USA
Stefano Galli, Italy

Key Speakers
Antonio Colombo, Alok Finn, Dinesh Shah, Edward Choke,
Sameer Dani, Sreekala Padmanabhan, Chieh Sui Tan, Narendra Khanna
Attend this session to:

- Learn about the emerging Sirolimus Coated Balloon (SCB) technology in Peripheral Vascular treatment.
- Learn about SCB with ‘NANOLUTE’ technology and it’s clinical outcome in Below the Knee (BTK) and Superficial Femoral Artery (SFA) indications.
- Learn about SCB with ‘NANOLUTE’ technology and it’s clinical outcome in Arteriovenous Fistula (AVF) and Arteriovenous Graft (AVG) indications.

**Agenda**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>Session Objectives - <em>Antonio Colombo</em></td>
<td></td>
</tr>
<tr>
<td>12:18</td>
<td>The Magic Touch - PTA - Sirolimus Coated Balloon - Insights from pre-clinical evaluation - <em>Aloke Finn</em></td>
<td></td>
</tr>
<tr>
<td>12:28</td>
<td>Science behind Nanolute Technology of Sirolimus Coated Balloon - <em>Dinesh Shah</em></td>
<td></td>
</tr>
<tr>
<td>12:38</td>
<td>XTOSI study: First in man study of clinical use and safety of Sirolimus Coated PTA Balloon in the treatment of infranqunial arterial disease - <em>Edward Choke</em></td>
<td></td>
</tr>
<tr>
<td>12:47</td>
<td>Sirolimus coated PTA balloon initial experience and case reports - <em>Edward Choke</em></td>
<td></td>
</tr>
<tr>
<td>12:57</td>
<td>Xtreme FIM: Clinical outcome and safety in peripheral vascular disease with Sirolimus Coated Balloon and case report - <em>Sameer Dani</em></td>
<td></td>
</tr>
<tr>
<td>13:07</td>
<td>Case 1 - <em>Sreekala Padmanabhan</em></td>
<td></td>
</tr>
<tr>
<td>13:16</td>
<td>Case 2 - <em>Sameer Dani</em></td>
<td></td>
</tr>
<tr>
<td>13:25</td>
<td>Sirolimus Coated Balloon for salvage thrombus Arteriovenous Graft - Interim results and future RCT design – <em>Chieh Suai Tan</em></td>
<td></td>
</tr>
<tr>
<td>13:35</td>
<td>Thrombolysis of Arteriovenous Graft and treatment with Sirolimus Coated Balloon - Case discussion - <em>Chieh Suai Tan</em></td>
<td></td>
</tr>
<tr>
<td>13:42</td>
<td>Session evaluation and key learnings - <em>Narendra Khanna</em></td>
<td></td>
</tr>
</tbody>
</table>
We are engaging with tomorrow, to better your today.

#HelloFuture
ABLUMINUS DES+
DESIGNED TO TREAT DIABETIC PATIENTS
ABILITY TO TREAT DIABETIC PATIENTS: DES + DCB STRATEGY

Chairpersons:
Roxana Mehran, USA
Gregg W. Stone, USA
Marie-Claude Morice, France

Panellists:
Antonio Colombo, Italy
Alexandre Abizaid, Brazil
Ashok Seth, India

Key Speakers
Roxana Mehran, Luca Testa, Sameer Dani, Azeem Latib, Alexandre Abizaid, Antonio Colombo, A B Gopalamurugan, Paolo Vicinelli, Marie-claude Morice.

Symposium 03
23 May – Thursday
12:15 – 13:45
Room No – 242B, Level 2
Attend this session to:
- Understand and discuss the need of dedicated DES for Diabetes Mellitus (DM) and Acute Myocardial Infarction (AMI) patients.
- Understand and learn benefits of DES+DCB strategy to provide uniform and homogenous drug delivery in patients with DM and AMI
- Learn about a DES with on label indication for DM and AMI

## Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>Session Objectives - Roxana Mehran</td>
</tr>
<tr>
<td>12:18</td>
<td>Why do we need a dedicated DES for diabetes? Introducing the Abluminus concept - Roxana Mehran</td>
</tr>
<tr>
<td>12:29</td>
<td>Abluminus DES: Real world registry data from en-ABL e Registry, DEDICATE Registry and beyond - Luca Testa</td>
</tr>
<tr>
<td>12:40</td>
<td>Case 1 - A patient with multivessel disease (MVD) including a calcified LAD/RCA stenosis - Sameer Dani</td>
</tr>
<tr>
<td>12:50</td>
<td>ABILITY randomised controlled trial for diabetic indication: Abluminus DES vs. Xience - Imaging study - Azeem Latib</td>
</tr>
<tr>
<td>13:01</td>
<td>Case 2 - Complex PCI with diabetic patient - A B Gopalamurugan</td>
</tr>
<tr>
<td>13:11</td>
<td>Case 3 - The Italian experience with Abluminus in unprotected left main - Paolo Vicinelli</td>
</tr>
<tr>
<td>13:22</td>
<td>ABILITY Global randomised controlled trial: Study design and clinical endpoints - Marie-Claude Morice</td>
</tr>
<tr>
<td>13:32</td>
<td>Future generation Abluminus np: Rationale and a concept - Alexandre Abizaid</td>
</tr>
<tr>
<td>13:42</td>
<td>Session evaluation and key learnings - Antonio Colombo</td>
</tr>
</tbody>
</table>
Redefining Boundaries.

#HelloFuture
Clinical Value of Sirolimus Coated Balloon Angioplasty in patients with Coronary Artery Disease: Long-term results from real-world Nanolute Registry

By
Dr. Sameer Dani
Imagine,
We’ve only just begun.

#HelloFuture
LATE BREAKING CLINICAL TRIAL

Clinical outcome of a Novel Sirolimus Coated Balloon In Patients with Coronary Artery Disease

By
Dr. Bernardo Cortese
E- Poster Presentation

Venue: Poster’s Lab, Level 3
No formal presentation is scheduled for the e-poster, they will be presented spontaneously on one of the touchscreens in the Posters’Lab.

- A Long-Term Outcome of Novel Abluminal Coated Sirolimus Eluting Coronary Stent in a real-world population: Data from All-comers en-ABL e-Registry: Dr. Sameer Dani

- Performance of Novel Abluminal coated Sirolimus Eluting Stent in small and large Coronary Vessels: Subgroup analysis from en-ABL e-Registry: Dr Luca Testa

- Impact and Performance of Abluminal coated Sirolimus Eluting Stent In Diabetic Population: Results from en-ABL e-Registry: Dr Luca Testa

- Three Year Outcome After Sirolimus Coated Balloon Angioplasty for In-Stent Restenosis: Dr. Bernardo Cortese

- Two-year follow-up of a real world multi-centre study assessing Sirolimus Coated Balloon in Small Coronary Vessels: Insights from the NANOLUTE Registry: Dr. Bernardo Cortese

- Sirolimus Coated Balloon in coronary intervention; short-term follow-up from a single centre registry: Dr. Sandeep Basavarajaiah
Unlocking the future, now.

#HelloFuture
Concept Medical